Fragment-Based Drug Discovery

Charles River has extensive capabilities in fragment-based drug discovery (FBDD), offering access to expertise in screening, structural biology as well as computational and medicinal chemistry. Our range of orthogonal fragment screening technologies allows us to customize a fragment-based lead discovery solution.

Our fragment-based drug discovery (FBDD) platform provides access to:

Orthogonal Screening Technologies Technologies include thermal shift assay, surface plasmon resonance (SPR) using Biacore™ instrumentation, isothermal titration calorimetry (ITC), NMR, high-concentration biochemical assay and X-ray crystallography
Structural Biology Experience in the development of structure routes to support FBDD; in-house X-ray facility and Crystal Bank of structures
Fragment Library
2,000 member library designed for fragment screening and rapid FBDD optimization of hits; kinase-specific and 19F fragment libraries also available
Computational Chemistry Proprietary fragment hit expansion techniques and fragment shape-based analysis tools
Medicinal Chemistry Expertise in structure-based drug discovery and fragment hit optimization

You may also be interested in...


We conduct hit-to-lead projects in an efficient cycle of rational design, synthesis and biological evaluation.

Integrated Drug Discovery

Integrated Drug Discovery

We operate as a proactive thinking partner bringing target to clinical candidate capabilities, ideas and solutions to your program.